17th May 2021
- 0 comments
ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a new class of interferon drugs, has announced the strengthening of its Board and Management as it prepares to advance its lead novel hybrid interferon drug candidate Alfacyte™.
...Register / Login now to read full story
In order to read the full story we need you to be registered with us, please click the links below to login or register.
Back to Homepage